Treatment of primary and metastatic breast and pancreatic tumors upon intravenous delivery of a PRDM14‐specific chimeric siRNA/nanocarrier complex

PRDM14 is highly expressed in several cancers but is not detected in normal tissues. It confers cancer stem cell‐like properties, including chemoresistance and distant metastasis, to cancer cells. Herein, we aimed to develop a highly effective therapy against advanced stage cancer based on intraveno...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of cancer 2021-08, Vol.149 (3), p.646-656
Hauptverfasser: Taniguchi, Hiroaki, Natori, Yukikazu, Miyagi, Yohei, Hayashi, Kotaro, Nagamura, Fumitaka, Kataoka, Kazunori, Imai, Kohzoh
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:PRDM14 is highly expressed in several cancers but is not detected in normal tissues. It confers cancer stem cell‐like properties, including chemoresistance and distant metastasis, to cancer cells. Herein, we aimed to develop a highly effective therapy against advanced stage cancer based on intravenously delivered PRDM14‐targeted siRNA. First, we examined PRDM14 expression and gene amplification in breast and pancreatic tumors and cell lines. PRDM14 was expressed in breast cancer, including the triple‐negative subtype, and pancreatic cancer. PRDM14 was amplified in 23.8% of patients with PRDM14+ breast cancer. Next, we investigated the inoculated tumor growth and distant metastasis following PRDM14 depletion by administering mice with PRDM14‐specific chimeric siRNA combined with a novel branched PEGylated poly‐L‐ornithine (PLO)‐based intravenous drug delivery system, designated PRDM14 unit polyion complex (uPIC) (n = 6/group). Inhibition of PRDM14 expression with PRDM14 uPIC by systemic intravenous injection effectively reduced tumor size and metastasis in vivo, thereby improving survival. Finally, pharmacokinetic/toxicokinetic analyses were performed on PRDM14 uPIC, which was intravenously administered to rats (n = 10‐15/group) and cynomolgus monkeys (n = 3‐5/group), twice weekly for 4 weeks. This revealed that PRDM14 uPIC was relatively nontoxic and the siRNA exposure in serum was greater than that predicted by the administered dose ratio when delivered as a uPIC. Taken together, our study indicated that PRDM14 uPIC is highly effective in suppressing malignant features of solid cancers and does not cause severe toxicity, making it a promising therapeutic agent for cancer treatment. What's new? The transcriptional regulator PRDM14 helps embryonic stem cells maintain pluripotency. Cancer cells that express it are more likely to have stem‐cell properties and metastasize. Here, the authors tested a small interfering RNA (siRNA) against PRDM14 as a therapy against advanced‐stage cancer. They used a novel delivery system that enhances accumulation of the siRNA in the tumors rather than the liver and the spleen. In animal models, they found that treatment of triple‐negative breast and pancreatic cancers with this agent reduced tumor size, prevented metastasis, and prolonged survival, and they observed no severe toxicity.
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.33579